4.7 Article

Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance

Journal

JOURNAL OF MOLECULAR BIOLOGY
Volume 434, Issue 9, Pages -

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jmb.2022.167503

Keywords

X-ray crystallography; protease inhibitors; structure-based drug design; structural biology; medicinal chemistry

Funding

  1. DOE Office of Science by Argonne National Laboratory [DE-AC0206CH11357]
  2. National Institute of Allergy and Infectious Diseases [R01 AI085051]
  3. National Institute of General Medical Sciences [R01 GM135919]
  4. National Institute of General Medical Sciences of the NIH [F31 GM119345, F31 GM131635]

Ask authors/readers for more resources

Third generation Hepatitis C virus (HCV) NS3/4A protease inhibitors, glecaprevir and voxilaprevir, show high efficacy against various genotypes and resistant variants. The fluorine substitutions on these inhibitors contribute to their improved potency and resistance profile, allowing them to adapt to structural changes induced by specific substitutions. A multi-disciplinary approach involving inhibitor design, enzyme inhibition assays, co-crystallography, and structural analysis was used to study the interactions between fluorinated inhibitors and the target protein, providing valuable insights for avoiding drug resistance.
Third generation Hepatitis C virus (HCV) NS3/4A protease inhibitors (PIs), glecaprevir and voxilaprevir, are highly effective across genotypes and against many resistant variants. Unlike earlier PIs, these compounds have fluorine substitutions on the P2-P4 macrocycle and P1 moieties. Fluorination has long been used in medicinal chemistry as a strategy to improve physicochemical properties and potency. However, the molecular basis by which fluorination improves potency and resistance profile of HCV NS3/4A PIs is not well understood. To systematically analyze the contribution of fluorine substitutions to inhibitor potency and resistance profile, we used a multi-disciplinary approach involving inhibitor design and synthesis, enzyme inhibition assays, co-crystallography, and structural analysis. A panel of inhibitors in matched pairs were designed with and without P4 cap fluorination, tested against WT protease and the D168A resistant variant, and a total of 22 high-resolution co-crystal structures were determined. While fluorination did not significantly improve potency against the WT protease, PIs with fluorinated P4 caps retained much better potency against the D168A protease variant. Detailed analysis of the co-crystal structures revealed that PIs with fluorinated P4 caps can sample alternate binding conformations that enable adapting to structural changes induced by the D168A substitution. Our results elucidate molecular mechanisms of fluorine-specific inhibitor interactions that can be leveraged in avoiding drug resistance.(c) 2022 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available